Drug_Name,STUDYID,YEAR,Country,Dataset,Patient_Count,Median_Age,Female_Percentage,Male_Percentage,Median_BMI,Smoking_History_Yes_Percentage,Total_ADL_Independence_Percentage,LHRH_Use_Percentage,Tumor_Stage_T1_Percentage,Tumor_Stage_T2_Percentage,Tumor_Stage_T3_Percentage,Tumor_Stage_T4_Percentage,Nodal_Stage_N0_Percentage,Nodal_Stage_N1_Percentage,Nodal_Stage_N2_Percentage,Nodal_Stage_N3_Percentage,Stage_I_Percentage,Stage_II_Percentage,Stage_III_Percentage,Diabetes_Mellitus_Percentage,Congestive_Heart_Failure_Percentage,Stroke_Percentage,Atrial_Fibrillation_Percentage,Myocardial_Infarction_Percentage,Neoadjuvant_Chemotherapy_Received_Percentage,Adjuvant_Chemotherapy_Received_Percentage,Postoperative_RT_Received_Percentage,Common_Neoadjuvant_Regimen_1,Common_Neoadjuvant_Regimen_2,Common_Adjuvant_Regimen_1,Common_Adjuvant_Regimen_2,Tamoxifen_Percentage,Letrozole_Percentage,Anastrozole_Percentage,Antidiarrheal_Agent_Probiotics_Percentage,Antiemetic_Agent_Percentage,Painkiller_Antipyretic_Percentage,Beds_Less_Than_200_Percentage,Beds_200_To_499_Percentage,Beds_Greater_Or_Equal_To_500_Percentage,Designated_Cancer_Hospital_Percentage,Months_Between_Surgery_And_Index_Date
Lenvatinib,LENV2023-US-001,2023,USA,MDV,350,68,35,65,27.5,42,85,12,15,25,30,30,45,25,15,15,20,30,35,18,7,4,9,5,10,25,30,Cisplatin + Gemcitabine,Paclitaxel + Carboplatin,5-FU + Leucovorin,Capecitabine,5,3,2,40,60,55,15,45,40,60,2
Lenvatinib,LENV2022-EU-002,2022,Germany,Claim Database,420,72,40,60,26.8,38,78,15,12,28,32,28,40,28,16,16,18,32,33,22,9,5,11,6,8,22,28,Docetaxel + Cisplatin,Gemcitabine + Carboplatin,FOLFOX,XELOX,6,4,3,45,65,60,20,50,30,70,3
Lenvatinib,LENV2024-JP-003,2024,Japan,MDV,280,65,30,70,24.5,35,90,10,18,22,35,25,50,20,15,15,25,28,32,15,6,3,8,4,12,28,32,S-1 + Cisplatin,Docetaxel + 5-FU,UFT,Capecitabine + Oxaliplatin,4,2,1,35,55,50,10,40,50,80,1
